AI assistant
IXICO PLC AGM Information 2024
7723_agm-r_2024-01-25_e74c7461-e00a-4392-a991-a1abc68a82fa.html
AGM Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 9610A
IXICO plc
25 January 2024
25 January 2024
IXICO plc
("IXICO" or the "Company")
Results of AGM
IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering insights in neuroscience announces that all resolutions put forward to its Annual General Meeting held earlier today were duly passed and the votes cast were as follows:
| RESOLUTION | VOTES FOR |
% | VOTES AGAINST |
% | VOTES TOTAL |
% ISC VOTED | VOTES WITHHELD |
|
| 1 | Reports and Accounts | 20,820,635 | 99.92% | 16,913 | 0.08% | 20,837,548 | 43.10 | 7,409 |
| 2a | Re-election of Mark Warne | 20,811,026 | 99.87% | 26,948 | 0.13% | 20,837,974 | 43.10 | 6,983 |
| 2b | Election of Dipti Amin | 20,814,152 | 99.92% | 17,113 | 0.08% | 20,831,265 | 43.08 | 13,692 |
| 3 | Appointment of Moore Kingston Smith Auditors | 20,819,713 | 99.88% | 24,122 | 0.12% | 20,843,835 | 43.11 | 1,122 |
| 4 | Allotment of Securities | 20,819,913 | 99.89% | 23,822 | 0.11% | 20,843,735 | 43.11 | 1,222 |
| 5 | * Disapply Pre-Emption Provisions | 20,800,863 | 99.80% | 42,572 | 0.20% | 20,843,435 | 43.11 | 1,522 |
* Special Resolution
Please note that a 'vote withheld' is not a vote under English Law and is not counted in the calculation
of the proportion of the votes 'for' and 'against' a resolution.
For further information please contact:
| IXICO plc | +44 (0) 20 3763 7499 | |
| Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
||
| Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) |
+44 (0) 20 7220 0500 | |
| Giles Balleny / Dan Hodkinson (Corporate Finance) Michael F Johnson / Tamar Cranford Smith (Sales) |
About IXICO
IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.
More information is available on www.IXICO.com and follow us on Twitter @IXICOnews
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGQKPBPPBKDKDB